MedTrace Logo

Inuniv and Working Memory

NCT01177306 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 18

Last updated 2014-07-28

No results posted yet for this study

Summary

Minimum 24 subjects aged 8-12 with a diagnosis of ADHD will be prescribed extended release guanfacine (Intuniv) to assess impact, if any, on working memory. Pre and post testing using a standardized battery of tests for effect on symptoms of ADHD and working memory will be administered and assessed.

Conditions

  • Attention Deficit Hyperactivity Disorder

Interventions

DRUG

extended release guanfacine

1-4 mg daily. Dose determined by response of ADHD symptoms to drug and by body mass limitations

Sponsors & Collaborators

  • Shire

    collaborator INDUSTRY

  • Lori A. Schweickert, MD

    lead INDIV

Principal Investigators

  • Lori A Schweickert, MD · 3-C Family Services

Study Design

Allocation
NA
Purpose
BASIC_SCIENCE
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
8 Years
Max Age
12 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2010-07-31
Primary Completion
2013-12-31
Completion
2014-05-31

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01177306 on ClinicalTrials.gov